乳腺癌放疗后心脏毒性危险因素分析
该回顾性队列纳入2005至2014年接受新辅助化疗的I-III期乳腺癌患者174例,中位随访117个月,10年≥3级心脏事件发生率为8.5%(95%CI 4.7%-13.6%)。淋巴结阳性患者发生心脏毒性风险为阴性者的3.30倍,且该关联在多变量调整后仍显著。
要点
- 10年≥3级心脏事件累积发生率为8.5%(95%CI 4.7%-13.6%)
- 淋巴结阳性患者心脏毒性风险显著升高(HR=3.30)
- 淋巴结阳性者更常接受蒽环类、内分泌治疗及区域淋巴结照射
核心结论
- 在冠脉钙化负荷低且放疗剂量总体较低的乳腺癌队列中,心脏毒性发生率低,但淋巴结阳性患者为特别高风险群体。
研究设计与样本
- 回顾性分析2005至2014年接受新辅助化疗的I-III期乳腺癌连续患者174例,中位随访117个月,采用竞争风险模型调整死亡风险。
主要发现
- 174例患者中位年龄47岁,10年≥3级心脏事件发生率为8.5%(95%CI 4.7%-13.6%),共观察到13例事件。
- 166例有影像资料的患者中78.9%无可测量冠脉钙化。
- 淋巴结阳性患者(N=75)发生心脏毒性的可能性为阴性者的3.30倍,且更常接受蒽环类、内分泌治疗及区域淋巴结照射(P<0.05)。
- 对年龄和吸烟状态进行多变量调整后,淋巴结阳性疾病仍与显著心脏事件风险增加相关(P<0.05)。
临床怎么用
- 对淋巴结阳性乳腺癌患者放疗后应加强心脏毒性随访监测。
- 针对淋巴结阳性亚组需优化治疗方案以降低心脏毒性风险。
局限性
- 回顾性队列设计,样本量有限(174例),事件数较少(13例)。
- 原文未报告冠脉钙化与心脏事件的具体关联数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Concern for cardiotoxicity after the treatment of breast cancer necessitates a better understanding of factors that may increase the risk of significant (grade ≥3) cardiac events. We investigated clinical factors, coronary artery calcium (CAC), and radiation therapy dose to cardiac structures as predictive post-radiation therapy cardiotoxicity risk factors. METHODS AND MATERIALS: We retrospectively analyzed a cohort of serial patients treated with neoadjuvant chemotherapy for stage I to III breast cancer from 2005 through 2014. We measured the incidence of cardiac events after treatment, adjusting for the competing risk of death. RESULTS: We identified 174 patients with a median follow-up of 117 months and a median age of 47 years. The 10-year incidence of grade ≥3 cardiac events was 8.5% (95% CI, 4.7%-13.6%) with 13 events observed. 78.9% of the 166 patients with available imaging had no measurable CAC. Patients with nodal positivity (N = 75) were 3 times more likely to develop cardiac toxicity (HR=3.30) and were more likely to receive anthracyclines, hormonal therapy, and regional nodal irradiation during treatment (P < 0.05). After multivariable adjustment for age and smoking status, nodal positive disease remained associated with increased risk of significant cardiac events (P < .05). CONCLUSIONS: In a cohort of patients with breast cancer with low CAC burden and overall low doses of radiation, we observed low rates of cardiotoxicity. However, our findings identify patients with nodal positive disease as a particularly high-risk group, suggesting that close follow-up and optimization of therapies for this subgroup is needed.
引用
- Guo FB, No HJ, Park NJ, et al. Risk Factors of Cardiotoxicity After Breast Cancer Radiation Therapy. Adv Radiat Oncol. 2025. PMID: 41333182. doi:10.1016/j.adro.2025.101911
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。